zolbetuximab,epirubicin
astellas
[]
investigators report benefit in patients with cldn18.2-positive, her2-negative locally advanced unresectable or metastatic gastric/gej adenocarcinoma treated with first-line zolbetuximab and mfolfox6. #gicsm #gi23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.